10 results
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
GVHD #Pathophys #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Therapeutic #Pathways #NEJM
Role of G6PD in Protection against Oxidative Damage #Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
Damage #Pathophys #Peds ... #Genetics #Honc ... #Favism #g6pd #NEJM
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers. MHC1 denotes
Pathophysiology #Honc ... #Pharm #PD1 #PDL1 ... MicrosatelliteInstability #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
Tumor Type #EBM #Honc ... #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
#Pathophys #Peds #Genetics #Honc #Favism #g6pd #NEJM
#Pathophys #Peds ... #Genetics #Honc ... #Favism #g6pd #NEJM
Immune Checkpoint–Blocking Antibodies Approved by the Food and Drug Administration #Pharm #Honc #Checkpoint #Blockade #FDA #Antibodies
Administration #Pharm ... #Honc #Checkpoint ... #Indications #NEJM
Effect of Tolvaptan on the Estimated Glomerular Filtration Rate (GFR). #EBM #Nephro #Pharm #Tolvaptam #PCKD #PolyCysticKidneyDisease
Filtration Rate (GFR ... #EBM #Nephro #Pharm ... PolyCysticKidneyDisease #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
Pathophysiology #IM #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Immunosuppression #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
oncogenic alterations: EGFR ... #Diagnosis #Honc ... #NSCLC #PDL1 #NEJM
Classes of Mutations in the Gene Encoding Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Depending on the
#Pharm #Pathophys ... #Pulm #Peds #CysticFibrosis ... ModulatorTherapy #NEJM